Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Go back to Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve| Edwards Lifesciences (NYSE: EW) | Delayed: 86.23 +0.35 (0.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $85.88 | 52 Week High | $166.87 | |||
| Open | $86.19 | 52 Week Low | $72.20 | |||
| Day High | $87.22 | P/E | 25.07 | |||
| Day Low | $85.46 | EPS | $3.44 | |||
| Volume | 1,225,523 | |||||
